

(19)



(11)

EP 2 080 765 A1

(12)

EUROPEAN PATENT APPLICATION

(43) Date of publication:
22.07.2009 Bulletin 2009/30

(51) Int Cl.:
C07F 9/6561 (2006.01)

(21) Application number: **09158866.5**

(22) Date of filing: **17.12.1998**

(84) Designated Contracting States:
**AT BE CH CY DE DK ES FI FR GB GR IE IT LI LU
MC NL PT SE**

(30) Priority: **19.12.1997 JP 35149997**

(62) Document number(s) of the earlier application(s) in
accordance with Art. 76 EPC:
98961385.6 / 1 043 327

(71) Applicant: **Takeda Pharmaceutical Company
Limited
Osaka 541-0045 (JP)**

(72) Inventors:
• **Ishikawa, Tomoyasu
Otsu-shi Shiga 520-0052 (JP)**

• **Hashiguchi, Shohei
Toyonaka-shi Osaka 560-0881 (JP)**
• **Iizawa, Yuji
Muko-shi Kyoto 617-0003 (JP)**

(74) Representative: **Weber, Thomas
Patentanwälte
von Kreisler Selting Werner
Deichmannhaus am Dom
Bahnhofsvorplatz 1
50667 Köln (DE)**

Remarks:

This application was filed on 27-04-2009 as a
divisional application to the application mentioned
under INID code 62.

(54) **Phosphonocephem Derivates, Their Production And Use**

(57) 7β -[2(Z)-ethoxyimino-2-(5-phosphonoamino-
1,2,4-thiadiazole-3-yl)acetamido]-3-[4-(1-methyl-4-py-
ridinio)-2-thiazolylthio]-3-cephem-4-carboxylate, its es-
ter or its salt, which has a superior anti-bacterial activity,

stability, absorbability, etc., and a pharmaceutical com-
position containing it, is provided.

EP 2 080 765 A1

Description

TECHNICAL FIELD

5 [0001] This invention relates to a novel cephem compound having excellent antibacterial activities on a broad range of Gram-positive and Gram-negative bacteria, especially *Staphylococcus aureus*, methicillin-resistant *Staphylococcus aureus* (MRSA) and a bacteria belonging to *Pseudomonas* and being sufficiently water-soluble, to a method of producing the compound and to a medicine, especially an antibacterial composition containing the compound.

10 BACKGROUND ART


[0002] Various cephem compounds having, at the 7-position, 2-(5-amino-1,2,4-thiadiazole-3-yl)-2(Z)-alkoxy-iminoacetamido group, and having, at the 3-position, 3- or 4-(pyridinium) thiazole-4-ylthio group or condensed heterocyclic ring-thio group containing N⁺ as a ring constituting atom, have been reported in JPA H9(1997)-100283. However these
15 compounds are not sufficiently soluble in water, and it is preferable to use solubilizing agents when these compounds are dissolved in water. Thus these compounds are not sufficiently satisfactory when they are used in a pharmaceutical preparation, especially for injection.

[0003] And various cephem compounds having, at the 7-position, 2-(5-phosphonoamino-1,2,4-thiadiazole-3-yl)-2(Z)-methoxyiminoacetamido group, and having at the 3-position, a substituted methyl, i.e., pyridiniummethyl group or
20 1-methylpyridiniumthiomethyl group which are different from substituted-(CH=CH)_n-S-group in chemical structure, have also been reported in JPA S59(1984)-31791.


[0004] Though some recently developed cephalosporin compounds have sufficient activity against methicillin-resistant *Staphylococcus aureus* (MRSA), they are poorly soluble in water or physiologically acceptable saline, which is necessary for administration, and have not been put into practical use. Thus creation of novel compounds overcoming these
25 problems has been desired.

DISCLOSURE OF INVENTION

[0005] Taking the foregoing circumstances into consideration, the present inventors diligently conducted extensive
30 studies and synthesized, for the first time, a cephem compound characterized by having, at the 3-position of its cephem, oxacephem or carbacephem nucleus, a group of the formula:



40 wherein one of R³ and R⁴ is a pyridinium group which may be substituted and the other is a hydrogen atom or hydrocarbon group which may be substituted, or R³ and R⁴ taken together may form a quaternized nitrogen-containing heterocyclic ring which may be substituted; X is a nitrogen atom or CH; and n is 0 or 1, and, at the 7-position, a group of the formula:




55 wherein R¹ is a phosphono group or a group convertible to a phosphono group; R² is a hydrogen atom or a group having a linkage through a carbon atom; Q is a nitrogen atom or CH, or an ester or salt thereof, and further found that the compound thus synthesized showed good solubility to water and has excellent medicinal properties such as antibacterial activity.

Based on these findings, the present invention was accomplished.


[0006] More specifically, the present invention relates to :

(1) A compound of the formula:






wherein R¹ is a phosphono group or a group convertible to a phosphono group; R² is a hydrogen atom or a group having a linkage through a carbon atom; each of Q and X is a nitrogen atom or CH; Y is S, O or CH₂; n is 0 or 1; one of R³ and R⁴ is a pyridinium group which may be substituted and the other is a hydrogen atom or hydrocarbon group which may be substituted, or R³ and R⁴ taken together may form a quaternalized nitrogen-containing heterocyclic ring which may be substituted, salt or ester thereof;


- 20
- (2) A compound according to the above (1), wherein R¹ is a phosphono group which may be protected;
- (3) A compound according to the above (1), wherein R¹ is phosphono, dialkoxo-phosphoryl, O-alkyl-phosphono, diamino-phosphoryl, (amino)(hydroxy)phosphoryl, (alkoxy)(morpholino)phosphoryl or dihalophosphoryl;
- 25
- (4) A compound according to the above (1), wherein R¹ is a phosphono group;
- (5) A compound according to the above (1), wherein Y is S;
- (6) A compound according to the above (1), wherein R² is a C₁₋₆ alkyl group which may be substituted or a C₃₋₅cycloalkyl group;
- (7) A compound according to the above (1), wherein R³ is a pyridinium group which may be substituted and R⁴ is a hydrogen atom;
- 30
- (8) A compound according to the above (1), wherein



is s



or



10 wherein R⁵ is a hydrocarbon group which may be substituted;

(9) A compound according to the above (1), wherein Q is a nitrogen atom;


(10) A compound according to the above (1), wherein X is a nitrogen atom;

(11) A compound according to the above (1), wherein n is 0;


15 (12) A compound according to the above (1), which is 7β-[2(Z)-ethoxyimino-2-(5-phosphonoamino-1,2,4-thiadiazole-3-yl)acetamido]-3-[4-(1-methyl-4-pyridinio)-2-thiazolythio]-3-cephem-4-carboxylate, its ester or its salt;

(13) A compound according to the above (1), which is 7β-[2(Z)-fluoromethoxyimino-2-(5-phosphonoamino-1,2,4-thiadiazole-3-yl)acetamido]-3-[4-(1-methyl-4-pyridinio)-2-thiazolythio]-3-cephem-4-carboxylate, its ester or its salt;

20 (14) A method for producing a compound shown in the above (1) which comprises reacting a compound of the formula:




30 wherein each symbol has the meaning given above, its ester or its salt, with a compound of the formula:



40 wherein each symbol has the meaning given above, its salt or its reactive derivative, if necessary, followed by converting R¹ to a phosphono group;

45 (15) A method for producing a compound shown in the above (1) which comprises subjecting a compound of the formula:



wherein one of R^{3'} and R^{4'} is a pyridyl group which may be substituted, and the other is a hydrogen atom or a hydrocarbon group which may be substituted, or R^{3'} and R^{4'}, taken together, represent a nitrogen-containing hete-

rocyclic ring which may be substituted, and the other symbols have the meanings given above, its ester or its salt to the nitrogen quaternization reaction in which quaternized-ammonium is formed, if necessary, followed by converting R¹ to a phosphono group;

(16) A pharmaceutical composition containing the compound as shown in the above (1);

(17) A pharmaceutical composition containing the compound shown in the above (1) and at least one of pharmaceutically acceptable carriers, diluents and bulking agents;

(18) A pharmaceutical composition as shown in the above (16) which is an anti-bacterial composition;

(19) A pharmaceutical composition as shown in the above (16) which is an anti-MRSA agent;

(20) A pharmaceutical composition as shown in the above (16) which is an injectable composition;

(21) Use of the compound as shown in the above (1) for producing a pharmaceutical composition;

(22) Use as shown in the above (21), wherein the pharmaceutical composition is an antibacterial agent;

(23) Use as shown in the above (21), wherein the pharmaceutical composition is an anti-MRSA agent;

(24) Use as shown in the above (21), wherein the pharmaceutical composition is an injectable composition;

(25) A method for treating a bacterial infection which comprises administering an effective amount of a compound as shown in the above (1) to a patient suffering from the bacterial infection;

(26) A method for treating a bacterial infection which comprises administering an effective amount of a compound as shown in the above (1) together with at least one of pharmaceutically acceptable carriers, diluents and excipients to a patient suffering from the bacterial infection;

(27) A method as shown in the above (25), wherein the bacterial infection is a MRSA infection; and

(28) A method as shown in the above (25), wherein the compound is administered by injection.

BEST MODE FOR CARRYING OUT THE INVENTION

[0007] The cephem compound in the present specification includes a group of compounds named on the basis of "cepham" disclosed in "The Journal of The American Chemical Society" Vol. 84, p.3400 (1962), which means a compound, among the cepham compounds, having a double bond at the 3, 4-positions.

[0008] Incidentally, the compounds of this invention include the compound of the formula (I) showing the free form or an ester or salt thereof (a salt of the compound (I) or a salt of the ester of the compound (I)). In the present specification, hereinafter, unless otherwise specified, the compound of the formula (I) shown in the free form or an ester or salt thereof is simply referred to as the compound (I) or the antibacterial compound (I).

Accordingly, the compound (I) in the present specification includes, usually, the free form as well as an ester or salt thereof.

[0009] R¹ is a phosphono group or a group convertible to a phosphono group. The group convertible to a phosphono group is a group which can be converted to a phosphono group, for example, by hydrolysis, substitution reaction, etc. Examples of the group convertible to phosphono group include, for example, dihalophosphoryl such as di-chlorophosphoryl, etc. in addition to a protected-phosphono group.

[0010] The protected-phosphono group is a phosphono group protected by a phosphono-protective group. In the field of nucleic acid, phosphono-protective groups have been sufficiently studied, and the method of a protecting phosphono group has been established. In the present invention also, conventional phosphono-protective groups can be adequately employed. Examples of protected-phosphono groups include mono-or di-ester phosphono group (e.g., dihalophosphoryl such as di-chlorophosphoryl, etc.; dialkoxy-phosphoryl group such as di-methoxyphosphoryl, di-ethoxyphosphoryl, di-propoxyphosphoryl, etc.; O-alkyl-phosphono group such as O-methyl phosphono, O-ethyl phosphono, etc.), mono-esterified mono-amidated phosphono group (e.g., mono-or di-amidated phosphono group such as diaminophosphoryl, (amino)(hydroxy)phosphoryl, etc.; (alkoxy)(amino)phosphoryl group such as (methoxy)(amino)phosphoryl, (ethoxy)(amino)phosphoryl, etc.; (alkoxy)(morpholino)phosphoryl group such as (methoxy)(morpholino)phosphoryl, (ethoxy)(morpholino)phosphoryl, etc.), etc. As R¹, phosphono, dialkoxy-phosphoryl, O-alkyl-phosphono, diaminophosphoryl, (amino)(hydroxy)phosphoryl, (alkoxy)(morpholino)phosphoryl or dihalophosphoryl are preferable, and phosphono is the most preferable.

[0011] R² is a hydrogen atom or a group having a linkage through a carbon atom. Examples of the group having a linkage through a carbon atom represented by R² include, for example, a hydrocarbon group which may be substituted (for example, an alkyl group which may be substituted, an alkenyl group which may be substituted, an alkynyl group which may be substituted, an aralkyl group which may be substituted, a cyclic hydrocarbon group which may be substituted), an acyl group or a non-aromatic heterocyclic group (having linkage at a carbon atom) which may be substituted. Among them, an alkyl group which may be substituted, an alkenyl group which may be substituted, a cyclic hydrocarbon group which may be substituted etc. are preferable. As the alkyl group in "an alkyl group which may be substituted", a C₁₋₆alkyl group, etc., are preferable, and methyl, ethyl, isopropyl, etc. are the most preferable. As the alkenyl group in "an alkenyl group which may be substituted", a C₂₋₆alkenyl group is preferable. As the alkynyl group in "an alkynyl group which may be substituted", a C₂₋₆alkynyl group is preferable. As the aralkyl group in "an aralkyl group which may be substituted", a C₇₋₂₀aralkyl group is preferable. Examples of the cyclic hydrocarbon group in "a cyclic hydrocarbon group

which may be substituted" include, a 3 to 7 membered non-aromatic cyclic hydrocarbon group such as cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl, cycloheptyl, 2-cyclopentene-1-yl, 3-cyclopentene-1-yl, 2-cyclohexene-1-yl, 3-cyclohexene-1-yl, etc., etc. Among them, a C₃₋₇cycloalkyl group such as cyclobutyl, cyclopentyl, etc. are preferable. Examples of the acyl group include, for example, a C₁₋₆alkanoyl group which may be substituted, a C₃₋₅alkenoyl group which may be substituted, a C₆₋₁₀aryl-carbonyl group which may be substituted, a heterocyclic carbonyl group, etc.

[0012] As the "optionally substituted C₁₋₆alkanoyl group", use is made of, for example, a C₁₋₆alkanoyl group which may optionally be substituted with 1 to 3 substituents selected from a halogen, oxo, a C₁₋₆alkoxy, a C₁₋₆alkanyl, a C₆₋₁₀aryl, a C₆₋₁₀aryloxy, and a C₆₋₁₀arylthio. More specifically, use is made of, for example, formyl, acetyl, propionyl, butyryl, valeryl, pivaloyl, succinyl, glutaryl, monochloroacetyl, dichloroacetyl, trichloroacetyl, monobromoacetyl, monofluoroacetyl, difluoroacetyl, trifluoroacetyl, monoiodoacetyl, acetoacetyl, 3-oxobutyryl, 4-chloro-3-oxobutyryl, phenylacetyl, p-chlorophenylacetyl, phenoxyacetyl and p-chlorophenoxyacetyl.

[0013] As the "optionally substituted C₃₋₅alkenoyl group", use is made of, for example, a C₃₋₅alkenoyl group optionally substituted with 1 to 3 substituents selected from a halogen and a C₆₋₁₀aryl, more specifically, for example, acryloyl, crotonoyl, maleoyl, cinnamoyl, p-chlorocinnamoyl and β-phenylcinnamoyl.

[0014] As the "optionally substituted C₆₋₁₀aryl-carbonyl group", use is made of, for example, a C₆₋₁₀aryl-carbonyl group optionally substituted with 1 to 3 substituents selected from a halogen, nitro, hydroxy, a C₁₋₆alkyl and a C₁₋₆alkoxy, more specifically, for example, benzoyl, naphthoyl, phthaloyl, p-toluoyl, p-tert-butylbenzoyl, p-hydroxybenzoyl, p-methoxybenzoyl, p-tert-butoxybenzoyl, p-chlorobenzoyl and p-nitrobenzoyl.

[0015] The "heterocyclic group" in "heterocyclic carbonyl group" means a group formed by removing one hydrogen atom linked to carbon atom of the heterocyclic ring. The heterocyclic ring means a 5-to 8-membered ring containing 1 to several, preferably 1 to 4 hetero-atoms such as a nitrogen atom which may be oxidized, oxygen atom and a sulfur atom, or a condensed ring thereof. As such a heterocyclic group, for example, 2- or 3-pyrrolyl; 3-, 4- or 5-pyrazoly; 2-, 4- or 5-imidazoly; 1,2,3- or 1,2,4-triazoly; 1H- or 2H-tetrazoly; 2- or 3-furyl; 2- or 3-thienyl; 2-, 4- or 5-oxazolyl; 3-, 4- or 5-isoxazolyl; 1,2,3-oxadiazol-4-yl or 1,2,3-oxadiazol-5-yl; 1,2,4-oxadiazol-3-yl or 1,2,4-oxadiazol-5-yl; 1,2,5- or 1,3,4-oxadiazoly; 2-, 4- or 5-thiazoly; 3-, 4- or 5-isothiazoly; 1,2,3-thiadiazol-4-yl or 1,2,3-thiadiazol-5-yl; 1,2,4-thiadiazol-3-yl or 1,2,4-thiadiazol-5-yl; 1,2,5- or 1,3,4-thiadiazoly; 2- or 3-pyrrolidinyl; 2-, 3- or 4-pyridyl; 2-, 3- or 4-pyridyl-N-oxido; 3- or 4-pyridazinyl; 3- or 4-pyridazinyl-N-oxido; 2-, 4- or 5-pyrimidinyl; 2-, 4- or 5-pyrimidinyl-N-oxido; pyrazinyl; 2-, 3- or 4-piperidinyl; piperazinyl; 3H-indol-2-yl or 3H-indol-3-yl; 2-, 3- or 4-pyranyl; 2-, 3- or 4-thiopyranyl; benzopyranyl; quinolyl; pyrido[2,3-d]pyrimidyl; 1,5-, 1,6-, 1,7-, 1,8-, 2,6- or 2,7-naphthyridyl; thieno[2,3-d]pyridyl; pyrimidopyridyl; pyrazinoquinolyl; and benzopyranyl can be used.

[0016] Examples of the non-aromatic heterocyclic group in "a non-aromatic heterocyclic group having a linkage at a carbon atom, which may be substituted" preferably include a 3 to 6 membered non-aromatic heterocyclic group containing 1 or 2 hetero atoms such as a nitrogen atom, an oxygen atom, a sulfur atom in addition to a carbon atom, such as oxylanyl, azetidanyl, oxetanyl, thietanyl, pyrrolidinyl, tetrahydrofuryl, thiolanyl, piperidyl, tetrahydropyranyl, morpholinyl, thiomorpholinyl.

[0017] Examples of the substituents, which the above-mentioned "hydrocarbon group" may optionally have, include a heterocyclic group, a hydroxyl group, a C₁₋₆alkoxy group, a C₃₋₁₀cycloalkyl group, a C₃₋₇cycloalkyloxy group, a C₆₋₁₀aryloxy group, a C₇₋₁₉aralkyloxy group, a heterocyclic-oxy group, a mercapto group, a C₁₋₆alkylthio group, a C₃₋₁₀cycloalkylthio group, a C₆₋₁₀arylthio group, a C₇₋₁₉aralkyl thio group, a heterocyclic-thio group, an amino group, a mono-C₁₋₆alkylamino group, a di-C₁₋₆alkylamino group, a tri-C₁₋₆alkyl ammonium group, a C₃₋₁₀cycloalkylamino group, a C₆₋₁₀arylaminio group, a C₇₋₁₉aralkylamino group, a heterocyclic amino group, a cyclic amino group, an azido group, a nitro group, a halogen atom, a cyano group, a carboxyl group, a C₁₋₁₀alkoxy-carbonyl group, a C₁₋₁₀aryloxy-carbonyl group, a C₇₋₁₉aralkyloxy-carbonyl group, a C₆₋₁₀aryl-carbonyl group, a C₁₋₆alkanoyl group, a C₃₋₅alkenoyl group, a C₆₋₁₀aryl-carbonyloxy group, a C₂₋₆alkanoyloxy group, a C₃₋₅alkenoyloxy group, an optionally substituted carbamoyl group, an optionally substituted thiocarbamoyl group, an optionally substituted carbamoyloxy group, a phthalimido group, a C₁₋₆alkanoylamino group, a C₆₋₁₀aryl-carbonylamino group, a C₁₋₁₀alkoxy-carboxamido group, a C₆₋₁₀aryloxy-carboxamido group and a C₇₋₁₉aralkyloxy-carboxamido group. The number of these substituents, which may be the same as or different from one another, ranges from 1 to 4.

[0018] Among specific examples of the above-mentioned substituents of the "hydrocarbon group", as the "optionally substituted carbamoyl group", use is made of, for example, a carbamoyl group and a cyclic aminocarbonyl group optionally substituted with one or two substituents selected from, for example, a C₁₋₆alkyl group, a C₆₋₁₀aryl group, a C₁₋₆alkanoyl group, a C₆₋₁₀arylcarbonyl group and a C₁₋₆alkoxy-phenyl group. More specifically, use is made of, for example, carbamoyl, N-methylcarbamoyl, N-ethylcarbamoyl, N,N-dimethylcarbamoyl, N,N-diethylcarbamoyl, N-phenylcarbamoyl, N-acetylcarbamoyl, N-benzoylcarbamoyl, N-(p-methoxyphenyl)carbamoyl, pyrrolidinocarbonyl, piperidinocarbonyl, piperazinocarbonyl and morpholinocarbonyl. As the "optionally substituted thiocarbamoyl group", use is made of a thiocarbamoyl group optionally substituted with one or two substituents selected from, for example, a C₁₋₆alkyl group and a C₆₋₁₀aryl group, which are exemplified by thiocarbamoyl, N-methylthiocarbamoyl and N-phenylthiocarbamoyl. As the "optionally substituted carbamoyloxy group", use is made of a carbamoyloxy group optionally substituted with one or


two substituents selected from, for example, a C₁₋₆alkyl group and a C₆₋₁₀aryl group. Specific examples include carbamoyloxy, N-methyl carbamoyloxy, N,N-dimethyl carbamoyloxy, N-ethyl carbamoyloxy and N-phenyl carbamoyloxy.

[0019] As the heterocyclic group and the heterocyclic group in the heterocyclic-oxy group, the heterocyclic-thio group and the heterocyclic amino group in the substituent of the "hydrocarbon group", use is made of group similar to those in the "heterocyclic carbonyl group" as mentioned above.

[0020] Examples of the substituent in the "non-aromatic heterocyclic group having a linkage at a carbon atom, which may be substituted" mentioned above include the embodiments mentioned as the hydrocarbon group and its substituent in the "hydrocarbon group which may be substituted".


[0021] As R², an optionally substituted hydrocarbon group is preferable. Examples of the "optionally substituted hydrocarbon group" shown by R³ include a C₁₋₆alkyl group optionally substituted with one to three substituents selected from, for example, a hydroxyl group, a C₃₋₁₀cycloalkyl group, a C₁₋₆alkoxy group, a C₁₋₆alkylthio group, an amino group, a halogen atom, carboxyl group, a C₁₋₁₀alkoxycarbonyl group, an optionally substituted carbamoyl group, a cyano group, an azido group and a heterocyclic group, which are more specifically exemplified by cyclopropylmethyl, methoxymethyl, ethoxymethyl, 1-methoxyethyl, 2-methoxyethyl, 1-ethoxyethyl, 2-hydroxyethyl, methylthiomethyl, 2-aminoethyl, fluoromethyl, 2-fluoroethyl, 2,2-difluoroethyl, chloromethyl, 2-chloroethyl, 2,2-dichloroethyl, 2,2,2-trichloroethyl, 2-bromoethyl, 2-iodoethyl, 2,2,2-trifluoroethyl, carboxymethyl, 1-carboxyethyl, 2-carboxyethyl, 2-carboxypropyl, 3-carboxypropyl, 1-carboxybutyl, cyanomethyl, 1-carboxy-1-methylethyl, methoxycarbonylmethyl, ethoxycarbonylmethyl, tert-butoxycarbonylmethyl, 1-methoxycarbonyl-1-methylethyl, 1-ethoxycarbonyl-1-methylethyl, 1-tert-butoxycarbonyl-1-methylethyl, 1-benzyloxycarbonyl-1-methylethyl, 1-pivaloyloxycarbonyl-1-methylethyl, carbamoylmethyl, N-methylcarbamoylmethyl, N,N-dimethylcarbamoylmethyl, 2-azidoethyl, 2-(pyrazolyl)ethyl, 2-(imidazolyl)ethyl, 2-(2-oxopyrrolidin-3-yl)ethyl and 1-carboxyl-1-(2,3,4-trihydroxyphenyl)methyl. Most preferable examples of R² include, for example, a straight chain or branched C₁₋₆alkyl group which may be substituted with one to three substituents selected from a halogen, a hydroxyl group, a C₁₋₆alkoxy group, a carboxyl group, a C₁₋₁₀alkoxy-carbonyl group, a cyano group, a carbamoyl group and a substituted carbamoyl, such as methyl, ethyl, n-propyl, isopropyl, butyl, isobutyl, sec-butyl, fluoromethyl, 2-fluoroethyl, 2-chloroethyl, 2-hydroxyethyl, 2-methoxyethyl, cyanomethyl, carboxymethyl, methoxycarbonylmethyl, ethoxycarbonylmethyl, carbamoylmethyl, N-methylcarbamoylmethyl, N,N-dimethylcarbamoylmethyl, etc., a C₃₋₅cycloalkyl group such as cyclopropyl, cyclobutyl, cyclopentyl, etc. and a C₃₋₅cycloalkyl-C₁₋₃alkyl group such as cyclopropylmethyl, etc. Among them, a C₁₋₆alkyl group which may be substituted and C₃₋₅cycloalkyl group are preferable.

[0022] One of R³ and R⁴ is a pyridinium group which may be substituted and the other is a hydrogen atom or a hydrocarbon group which may be substituted, or R³ and R⁴, taken together, represent a heterocyclic group which may be substituted containing a quaternized nitrogen. Examples of the "pyridinium group which may be substituted" include, for example, a group of the formula:




wherein R⁵ is a hydrocarbon group which may be substituted, R is a C₁₋₆alkyl group, a C₁₋₆alkoxy group, a C₁₋₆alkoxy-carbonyl group, an amino group, a nitro group, a halogen atom or a carboxy group, p is an integer of from 0 to 4, etc.

[0023] In case that R³ and R⁴, taken together, represent a heterocyclic group containing a quaternized nitrogen, which may be substituted, the group of the formula:



includes 6 membered unsaturated heterocyclic groups such as




20 wherein q is an integer of 0 to 3, and the other symbols have the meanings given above, etc.
 Examples of the "hydrocarbon group which may be substituted" represented by R³, R⁴ or R⁵ include those mentioned in the explanation of "a group having a linkage through a carbon atom" represented by R².

[0024] Each of p and q is preferably 0.

25 [0025] R⁵ is preferably is a C₁₋₄alkyl group such as methyl, etc. Referring to R³ and R⁴, it is preferable that R³ is a pyridinium group which may be substituted and R⁴ is a hydrogen atom, or that R³ and R⁴, taken together, represent a 6 membered unsaturated heterocyclic group having a quaternized nitrogen atom. Each of Q and X is preferably a nitrogen atom or CH. Each of Q and X is preferably a nitrogen atom.

Y is S, O or CH₂. Y is preferably S. That is, among the compound (I), a compound of the formula:



40 wherein each symbol has the meaning given above, its ester or its salt is preferable. While n can be 0 or 1, it is preferably 0.

45 [0026] In the above-mentioned compound (I), the mark [-] attached on the right shoulder of-COO at the 4-position shows that the carboxyl group forms carboxylate anion, making a pair with the positive charge on the pyridine ring (hereinafter sometimes simply referred to as A⁺). On the other hand, the compound (I) may optionally form a pharmaceutically acceptable ester or salt. As the pharmaceutically acceptable salt, use is made of, for example, inorganic basic salts, ammonium salts, organic basic salts, inorganic acid addition salts, organic acid addition salts and basic amino acid salts. As the inorganic base capable of forming the inorganic basic salt, use is made of, for example, alkali metal (e. g. sodium and potassium) and alkaline earth metals (e.g. calcium); as the organic base capable of forming the organic basic salt, use is made of, for example, procaine, 2-phenylethyl benzylamine, dibenzylethylenediamine, ethanolamine, diethanolamine, trishydroxymethylaminomethane, polyhydroxyalkylamine and N-methylglucosamine; as an inorganic acid capable of forming the inorganic acid addition salt, use is made of, for example, hydrochloric acid, hydrobromic acid, sulfuric acid, nitric acid and phosphoric acid; as an organic acid capable of forming the organic acid addition salt, use is made of, for example, p-toluenesulfonic acid, methanesulfonic acid, formic acid, trifluoroacetic acid and maleic acid; and, as a basic amino acid capable of forming the basic amino acid salt, use is made of, for example, lysine, arginine, ornithine and histidine. Among these salts, a basic salt (i.e. an inorganic basic salt, an ammonium salt, an organic basic salt and a basic amino acid salt) means that capable of being formed in the case where a basic group such as amino group, a monoalkylamino group, a dialkylamino group, a cycloalkylamino group, an arylamino group, an aralkylamino group, a cyclic amino group and a N-containing heterocyclic group exists in the substituent R¹, R² or R⁵

55

of the compound (I). And, examples of the acid addition salt include a salt in which the substituent at 4-position is a carboxyl group (COOH) and the substituent at 3-position is $-(CH=CH)_n-S-A^+Z^-$ [wherein Z stands for anion formed by removing proton H^+ from the inorganic acid or the organic acid, the anion being exemplified by a chloride ion, a bromide ion, a sulfate ion, a p-toluenesulfonate ion, a methanesulfonate ion and a trifluoroacetate ion, etc.] the salt being formed by adding one mole of acid to the moiety forming the internal salt of the compound (I), i.e. the carboxylate moiety (COO^-) at the 4-position and heterocyclic ring moiety at the 3-position. The ester derivative of the compound (I) means an ester producible by esterifying the carboxyl group in the molecule which is utilizable as an intermediate of the synthesis and is metabolically unstable and a non-toxic ester. Examples of the ester utilizable as intermediate of the synthesis include an optionally substituted C_{1-6} alkyl ester, a C_{2-6} alkenyl ester, a C_{3-10} cycloalkyl ester, a C_{3-10} cycloalkyl- C_{1-6} alkyl ester, an optionally substituted C_{6-10} aryl ester, an optionally substituted C_{7-12} aralkyl ester, a di- C_{6-10} aryl-methyl ester, a tri- C_{6-10} aryl-methyl ester, a substituted silyl ester and a C_{2-6} alkanoyloxy- C_{1-6} alkyl ester.

[0027] As the "optionally substituted C_{1-6} alkyl ester", use is made of, for example, methyl, ethyl, n-propyl, isopropyl, n-butyl, isobutyl, sec-butyl, tert-butyl, n-pentyl and n-hexyl, which may be substituted with one to three of, for example, benzyloxy, a C_{1-4} alkyl sulfonyl (e.g. methyl sulfonyl), trimethylsilyl, a halogen (e.g. fluorine, chlorine and bromine), acetyl, nitrobenzoyl, mesylbenzoyl, phthalimido, succinimide, benzenesulfonyl, phenylthio, a di- C_{1-4} alkylamino (e.g. dimethylamino), pyridyl, a C_{1-4} alkyl sulfinyl (e.g. methyl sulfinyl) and cyano. Examples of such groups include benzyloxymethyl, 2-methylsulfonylethyl, 2-trimethylsilylethyl, 2,2,2-trichloroethyl, 2-iodoethyl, acetylmethyl, p-nitrobenzoylmethyl, p-mesylbenzoylmethyl, phthalimidomethyl, succinimidomethyl, benzenesulfonylmethyl, phenylthiomethyl, dimethylaminoethyl, pyridine-oxido-2-methyl, methylsulfinylmethyl and 2-cyano-1,1-dimethylethyl.

[0028] As the C_{2-6} alkenyl group forming the " C_{2-6} alkenyl ester", use is made of, for example, vinyl, allyl, 1-propenyl, isopropenyl, 1-butenyl, 2-butenyl, 3-butenyl, methallyl, 1,1-dimethylallyl and 3-methyl-3-butenyl.

[0029] As the C_{3-10} cycloalkyl group forming the " C_{3-10} cycloalkyl ester", use is made of, for example, cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl, cycloheptyl, norbornyl and adamantyl.

[0030] As the C_{3-10} cycloalkyl- C_{1-6} alkyl group forming the " C_{3-10} cycloalkyl- C_{1-6} alkyl ester", use is made of, for example, cyclopropylmethyl, cyclopentylmethyl and cyclohexylmethyl.

[0031] As the " C_{6-10} aryl group" forming the "optionally substituted C_{6-10} aryl ester", use is made of, for example, phenyl, α -naphthyl, β -naphthyl and biphenyl, which may optionally be substituted with one to three of, for example, nitro and a halogen (e.g. fluorine, chlorine and bromine). The above group is specifically exemplified by p-nitrophenyl and p-chlorophenyl.


[0032] As the " C_{7-12} aralkyl group" forming the "optionally substituted C_{7-12} aralkyl ester", use is made of, for example, benzyl, 1-phenylethyl, 2-phenylethyl, phenylpropyl and naphthylmethyl, which may optionally be substituted with one to three of, for example nitro, a C_{1-4} alkoxy (e.g. methoxy), a C_{1-4} alkyl (e.g. methyl and ethyl) and hydroxy. Specific examples of such group include p-nitrobenzyl, p-methoxybenzyl and 3,5-di-tert-butyl-4-hydroxybenzyl.

[0033] As the di- C_{6-10} aryl-methyl group forming the "di- C_{6-10} aryl-methyl ester", use is made of, among others, benzhydryl; as the tri- C_{6-10} aryl-methyl group forming the tri- C_{6-10} aryl-methyl ester, use is made of, among others, trityl; as the substituted silyl group forming the substituted silyl ester, use is made of, for example, trimethylsilyl, tert-butyl dimethylsilyl and $-Si(CH_3)_2CH_2CH_2Si(CH_3)_2-$. As the C_{2-6} alkanoyloxy- C_{1-6} alkyl ester, use is made of, for example, acetoxymethyl ester. Examples of the above-mentioned ester include an ester at 4-position. The compound, wherein the substituent at 4-position is the above-mentioned ester group, forms a salt in which the substituent at 3-position is $-(CH=CH)_n-S-A^+Z^-$ [wherein symbols are of the same meaning as defined above].


[0034] The present invention includes, besides the above-described ester derivatives, pharmacologically acceptable compounds convertible into the compound (I) in vivo.

[0035] The compound (I) and starting compounds of this invention, in case that n is 1, include cis-isomer (Z-compound), trans-isomer (E-compound) and a cis-trans mixture. The compound (I) of this invention is preferably a trans-isomer (E-compound).

[0036] Referring to the compound (I), the cis-isomer (Z-compound), for example, means one of the geometrical isomers having the partial structure represented by the formula:



, and the trans-isomer means a geometrical isomer having the partial structure of the formula:



5

[0037] Among the compound (I), for example, 7 β -[2(Z)-ethoxyimino-2-(5-phosphonoamino-1,2,4-thiadiazole-3-yl)acetamido]-3-[4-(1-methyl-4-pyridinio)-2-thiazolythio]-3-cephem-4-carboxylate, its ester, its salt, 7 β -[2(Z)-fluoromethoxyimino-2-(5-phosphonoamino-1,2,4-thiadiazole-3-yl)acetamido]-3-[4-(1-methyl-4-pyridinio)-2-thiazolythio]-3-cephem-4-carboxylate, its ester and its salt, are especially preferable.

10

[0038] In the present specification, specific examples of the respective substituents are, unless specifically described, as follows. halogen : fluoro, chloro, bromo, iodo, etc.; C₁₋₄alkyl group : methyl, ethyl, propyl, isopropyl, butyl, isobutyl, t-butyl, etc.;

C₁₋₆alkyl group : the above mentioned C₁₋₄alkyl group and pentyl, 2,2-dimethyl propyl, hexyl, etc.;

15

C₂₋₆alkenyl group : vinyl, allyl, 1-propenyl, isopropenyl, 1-butenyl, 2-butenyl, 3-butenyl, methallyl, 1,1-dimethyl allyl, etc.;

C₂₋₆alkynyl group : ethynyl, 1-propynyl, 2-propynyl, 2-butylnyl, 2-pentylnyl, 2-hexynyl, etc.;

C₃₋₅cycloalkyl group : cyclopropyl, cyclobutyl, cyclopentyl, etc.;

C₃₋₁₀cycloalkyl group : the above mentioned C₃₋₅cycloalkyl group and cyclohexyl, cycloheptyl, cyclooctyl, cyclodecyl, etc.;

C₆₋₁₀aryl group : phenyl, naphthyl, etc.;

20

C₇₋₂₀aralkyl group : benzyl, 1-phenyl ethyl, 2-phenyl ethyl, phenyl propyl, naphthyl methyl, benzhydryl, etc.;

C₁₋₆alkoxy group : methoxy, ethoxy, propoxy, isopropoxy, butoxy, isobutoxy, t-butoxy, pentyloxy, 2,2-dimethyl propyloxy, hexyloxy, etc.;

C₃₋₇cycloalkyloxy group : cyclopropyloxy, cyclobutyloxy, cyclopentyloxy, cyclohexyloxy, etc.;

C₆₋₁₀aryloxy group : phenoxy, naphthyloxy, etc.;

25

C₇₋₁₉aralkyl-oxy group : benzyloxy, 1-phenylethyloxy, 2-phenylethyloxy, benzhydryloxy, etc.;

C₁₋₆alkyl-thio group : methylthio, ethylthio, propylthio, butylthio, isobutylthio, t-butylthio, pentylthio, 2,2-dimethylpropylthio, hexylthio, etc.;

C₃₋₁₀cycloalkyl-thio group : cyclopropylthio, cyclobutylthio, cyclopentylthio, cyclohexylthio, cycloheptylthio, cyclooctylthio, cyclodecylthio, etc.;

30

C₆₋₁₀aryl-thio group : phenylthio, naphthylthio, etc.;

C₇₋₁₉aralkyl-thio group : benzylthio, phenylethylthio, benzhydrylthio, tritylthio, etc.;

C₁₋₄alkyl-sulfinyl group : methylsulfinyl, ethylsulfinyl, propylsulfinyl, isopropylsulfinyl, butylsulfinyl, t-butylsulfinyl, etc.;

C₁₋₄alkyl-sulfonyl group : methylsulfonyl, ethylsulfonyl, propylsulfonyl, isopropylsulfonyl, butylsulfonyl, isobutylsulfonyl, t-butylsulfonyl, etc.;

35

mono-C₁₋₆alkyl-amino group : methylamino, ethylamino, n-propylamino, n-butylamino, etc.;

di-C₁₋₄alkyl-amino group : dimethylamino, diethylamino, methylethylamino, di-(n-propyl)amino, di-(n-butyl)amino, etc.;

di-C₁₋₆alkyl-amino group : the above mentioned di-C₁₋₄alkyl amino group and di-(pentyl)amino, di-(n-hexyl)amino, etc.;

tri-C₁₋₆alkyl-ammonium group : trimethylammonium, etc.;

C₃₋₁₀cycloalkyl-amino group : cyclopropylamino, cyclopentylamino, cyclohexylamino, etc.;

40

C₆₋₁₀aryl-amino group : anilino, N-methylanilino, etc.;

C₇₋₁₉aralkyl-amino group : benzylamino, 1-phenylethylamino, 2-phenylethyl amino, benzhydrylamino, etc.;

Cyclic amino group : pyrrolidino, piperidino, piperazinyl, morpholino, 1-pyrrolyl, etc.;

C₁₋₆alkanoyl amino group : acetamido, propionamido, butyroamido, valeroamido, pivaloamido, etc.;

C₆₋₁₀aryl-carbonyl amino group : benzamido, naphthoylamido, phthalimide, etc.;

45

C₁₋₆alkanoyl group : formyl, acetyl, propionyl, butyryl, valeryl, pivaloyl, succinyl, glutaryl, etc.;

C₂₋₆alkanoyloxy group : acetoxyl, propionyloxy, butyryloxy, valeryloxy, pivaloyloxy, etc.;

C₃₋₅alkenoyl group : acryloyl, crotonoyl, maleoyl, etc.;

C₃₋₅alkenoyloxy group : acryloyloxy, crotonoyloxy, maleoyloxy, etc.;

C₆₋₁₀aryl-carbonyl group : benzoyl, naphthoyl, phthaloyl, phenyl acetyl, etc.;

50

C₆₋₁₀aryl-carbonyloxy group : benzoyloxy, naphthoyloxy, phenylacetoxyl, etc.;

C₁₋₆alkoxy-phenyl group : methoxyphenyl, ethoxyphenyl, propoxyphenyl, butoxy phenyl, t-butoxyphenyl, etc.;

C₁₋₁₀alkoxy-carbonyl group : methoxycarbonyl, ethoxycarbonyl, propoxycarbonyl, isopropoxycarbonyl, butoxycarbonyl, isobutoxycarbonyl, t-butoxycarbonyl, pentyloxycarbonyl, 2,2-dimethylpropyloxycarbonyl, hexyloxycarbonyl, heptyloxycarbonyl, decyloxycarbonyl, etc.;

55

C₂₋₁₀alkenyloxy-carbonyl group : allyloxycarbonyl, etc.;

C₆₋₁₀aryloxy-carbonyl group : phenoxy carbonyl, naphthoxy carbonyl, etc.;

C₇₋₁₉aralkyl-oxycarbonyl group : benzyloxycarbonyl, benzhydryloxycarbonyl, etc.;

C₁₋₁₀alkoxy-carboxamido group : methoxycarboxamido (CH₃OCONH-), ethoxycarboxamido, tert-butoxycarboxamido,

etc.;

C₆₋₁₀aryloxy-carboxamido group : phenoxycarboxamido (C₆H₅OCONH-), etc.

[0039] Methods of producing the compound (I) of this invention are hereinafter described in detail.

5 Production method (1) :

[0040] The compound (I) can be synthesized by allowing, for example, a compound of the formula (II) or an ester or salt thereof (hereinafter referred to as Compound (II)) to react with a compound of the formula (III) or its salt or a reactive derivative thereof (hereinafter referred to as Compound (III)), followed by removing the protective group so as to change the group R¹ to a phosphono group.

[0041] The present method is to acylate a compound (II) by using compound (III). Compound (II) can be used as it is, and can also be used as its salt or its ester.

[0042] Examples of the salts of Compound (II) include an inorganic basic salt, an ammonium salt, an organic basic salt, an inorganic acid addition salt and an organic acid addition salt. Examples of inorganic basic salts include an alkali metal salt (e.g. sodium salt and potassium salt) and an alkaline earth metal salt (e.g. calcium salt); examples of an organic basic salt include trimethylamine salt, triethylamine salt, tert-butyl dimethylamine salt, dibenzylmethylamine salt, benzyl dimethylamine salt, N,N-dimethylaniline salt, pyridine salt and quinoline salt; examples of the inorganic acid addition salts include hydrochloride, hydrobromide, sulfate, nitrate and phosphate; and examples of the organic acid addition salts include formate, acetate, trifluoroacetate, methanesulfonate and p-toluenesulfonate.


[0043] As the ester of amino compound (II), mention is made of esters already described as the ester derivatives of compound (I), as exemplified by, more specifically, a C₁₋₆alkyl ester, a C₂₋₆alkenyl ester, a C₃₋₁₀cycloalkyl ester, a C₃₋₆cycloalkyl-C₁₋₆alkyl ester, a C₆₋₁₀aryl ester, a C₇₋₁₂aralkyl ester, a di-C₆₋₁₀arylmethyl ester, a tri-C₆₋₁₀arylmethyl ester and a C₂₋₆alkanoyloxy-C₁₋₆alkyl ester.

[0044] Compound (II) can be produced by the method shown in, for example, JPA-H9(1997)-100283, etc.

[0045] In this method, Compound (III) in the free state or in the form of a salt or reactive derivative thereof can be used as an agent for acylating the amino group at the 7-position of Compound (III). Examples of the salts of Compound (III) includes inorganic basic salts and organic basic salts. Examples of inorganic basic salts include alkali metal salts (e.g. sodium salt and potassium salt) and alkaline earth metal salts (e.g. calcium salt); examples of the organic basic salts include trimethylamine salt, triethylamine salt, tert-butyl dimethylamine salt, dibenzylmethylamine salt, benzyl dimethylamine salt, N,N-dimethylaniline salt, pyridine salt and quinoline salt.

[0046] In this method, the compound (III) as it is, its salt or its reactive derivative is used as an acylating agent for acylation of the amino group at the 7-position of amino compound. Examples of the salt of compound (III) include an inorganic base salt and an organic base salt. Examples of the inorganic base salt include alkali metal salt (e.g. sodium salt, potassium salt, etc.), alkaline earth metal salt (e.g., calcium salt, etc.), etc., and examples of the organic base salt include trimethylamine salt, triethylamine salt, tert-butyl dimethylamine salt, dibenzyl methylamine salt, benzyl dimethylamine salt, N,N-dimethylaniline salt, pyridine salt, quinoline salt etc. Examples of the reactive derivative of the carboxylic acid (III) include, for example, acid halides, acid azides, acid anhydrides, mixed acid anhydrides, active amides, active esters, active thio esters, etc. Examples of the acid halides include, for example, acid chloride, acid bromide, etc.; examples of the mixed acid anhydrides include mono-C₁₋₆alkyl-carbonic acid mixed acid anhydrides (e.g. mixed acid anhydride of free acid and monomethylcarbonic acid, monoethylcarbonic acid, mono-isopropylcarbonic acid, mono-isobutylcarbonic acid, mono-tert-butylcarbonic acid, mono-benzylcarbonic acid, mono-(p-nitrobenzyl)carbonic acid, mono-allylcarbonic acid, etc.), a C₁₋₆ aliphatic carboxylic acid mixed acid anhydride (e.g. mixed acid anhydride of free acid and acetic acid, trichloroacetic acid, cyanoacetic acid, propionic acid, butyric acid, isobutyric acid, valeric acid, isovaleric acid, pivalic acid, trifluoroacetic acid, trichloroacetic acid, acetoacetic acid, etc.), a C₇₋₁₂ aromatic carboxylic acid mixed acid anhydride (e.g. mixed acid anhydride of free acid and benzoic acid, p-toluic acid, p-chloro benzoic acid, etc.), organic sulfonic acid mixed acid anhydrides (e.g. mixed acid anhydride of free acid and methanesulfonic acid, ethane sulfonic acid, benzenesulfonic acid, p-toluenesulfonic acid, etc.) etc.; examples of the active amide include an amide with a nitrogen-containing heterocyclic compound (acid amide of a free acid and, for example, pyrazole, imidazole, benzo triazole, etc., these nitrogen-containing heterocyclic compound may be substituted with a C₁₋₆alkyl group (e.g., methyl, ethyl, etc.), a C₁₋₆alkoxy group (e.g., methoxy, ethoxy, etc.), a halogen atom (e.g., fluorine, chlorine, bromine, etc.), an oxo group, a thioxo group, a C₁₋₆alkylthio group (e.g., methylthio, ethylthio, etc.), etc.), etc.

[0047] As an active ester, all the active esters used in the field of the synthesis of β-lactam and peptide may be used. Examples of the active ester include, for example, an organic phosphoric acid ester (e.g. di-ethoxyphosphoric acid ester, di-phenoxyphosphoric acid ester, etc.), p-nitrophenyl ester, 2,4-di-nitrophenyl ester, cyanomethyl ester, pentachlorophenyl ester, N-hydroxysuccinimide ester, N-hydroxy phthalimide ester, 1-hydroxy benzotriazole ester, 6-chloro-1-hydroxy-benzotriazole ester, 1-hydroxy-1H-2-pyridone ester, etc. Examples of the active thio ester include an ester of the acid with an aromatic heterocyclic thiol compound (e.g. 2-pyridylthiol ester, 2-benzothiazolylthiol ester, etc., which heterocyclics may be substituted with a C₁₋₆alkyl group (e.g. methyl, ethyl, etc.), a C₁₋₆alkoxy group (e.g., methoxy, ethoxy, etc.),




wherein R^6 and R^7 represent, the same or different, a protecting group of phosphono group, the other symbols have the meanings given above, or a salt thereof (hereinafter sometimes referred to as Compound (1b)) to the deprotection reaction so that the protected phosphono group is deprotected.

Examples of the protecting group of a phosphono group represented by R^6 or R^7 include, for example, a halogen (e.g. chlorine atom, etc.), an alkoxy (e.g., a C_{1-3} alkoxy group such as methoxy, ethoxy, propoxy, etc.), amino, morpholino, thiomorpholino, etc.

The present method can be carried out, for example, by reacting Compound (1b) with a halogenated trimethylsilyl such as trimethylsilyl bromide, trimethylsilyl iodide, trimethylsilyl chloride, etc., a metal halide such as sodium iodide, potassium iodide, sodium bromide, etc., an alkali metal thiocyanate such as sodium thiocyanate, potassium thiocyanate, etc., etc. The reaction is carried out in a solvent which does not interfere with the reaction, though examples of the preferable solvent include methylene chloride, dimethylacetamide, etc. The reaction temperature is not limiting and the reaction is carried out usually under cooling or under mild conditions like slight heating.

[0051] When R^6 and R^7 in Compound (1b) are different, a protecting group of only one of R^6 and R^7 in Compound (1b) can be removed by selecting the reaction condition. In this case, compound of the formula:



wherein each symbol has the meaning given above, or salt thereof (hereinafter sometimes referred to as Compound (1c)) is obtained.


Production method (3):

[0052] Compound (1a) can be produced, for example, by subjecting Compound (1c) to a deprotecting reaction for removing the protecting group of the phosphono group.

[0053] The present method can be carried out, for example, by treating Compound (1c) with an acid. The acid may be an organic acid or an inorganic acid. Preferable examples of the acid include, for example, formic acid, sulfuric acid, trifluoroacetic acid, benzenesulfonic acid, nitric acid, P-toluenesulfonic acid, hydrochloric acid, etc. More preferable examples of the acid include, for example, formic acid, trifluoroacetic acid, hydrochloric acid, etc. The acid suitable for the reaction is selected by taking the group which is hydrolyzed into consideration. The reaction can be carried out with or without a solvent. Examples of the suitable solvent include an organic solvent, water, mixed solvent thereof, etc., which is usually used as a solvent. When trifluoroacetic acid is used, the reaction is preferably carried out in the presence of anisole.

Production method (4)

[0054] Compound (1) can be produced by condensing a compound of the formula:



10

wherein each symbol has the meaning given above, or a salt thereof (hereinafter sometimes referred to as Compound (V)) and a phosphoric acid derivative.

15

[0055] The reaction can be carried out by using Compound (V) or a salt thereof and a phosphorus halide such as phosphorus trichloride, phosphorus pentachloride, etc., etc. The reaction is usually carried out in a solvent such as a halogenated alkylene (e.g. methylene chloride, ethylene chloride, etc.), toluene, etc. The reaction temperature is not limiting and the reaction is carried out usually under cooling, an ambient temperature or under mild conditions like slight heating. In this reaction, when the reaction mixture contains Compound (I) wherein R¹ is dihalophosphoryl group, the reaction mixture may further be treated either with water to give Compound (I) wherein R¹ is phosphono group or with an alcohol (alkanol such as methanol, ethanol, etc.) to give Compound (I) wherein R¹ is an esterified phosphono group.


20

[0056] Compound (I) produced by the above production methods (1) to (4) can be isolated and purified by known methods, for example, extraction, column chromatography, precipitation, recrystallization, etc. On the other hand, isolated Compound (I) can be converted to a physiologically acceptable salt by a known method.

25

[0057] The method for producing the starting compound (III) is explained as follows :

30



35

or a reaction derivative at the carboxylic acid or its salt


or its salt

40

Production D \downarrow Introduction of a phosphono or protected phosphono group to amino group

Production B \downarrow Introduction of a phosphono or protected phosphono group to amino group

45



50

Production A


55

[0058] In the above formulas, R⁸ is the ester part of the esterified carboxylic group represented by the formula: CO₂R⁸. A compound of the formula (VII) or salt (hereinafter referred to sometimes as Compound (VII)) can be produced by subjecting a compound of the formula (VI), its reactive derivative or its salt (hereinafter sometimes referred to as Compound (VI)) to esterification.

[0059] Examples of the preferable salts of Compound (VI) include, for example, a metal salt such as an alkali metal salt (e.g., sodium salt, potassium salt, etc.), an alkaline earth metal salt (e.g., calcium salt, magnesium salt, etc.),

ammonium salt, an organic salt such as trimethylamine salt, triethylamine salt, pyridine salt, picoline salt, di-cyclohexylamine salt, N,N'-dibenzyl amine salt, etc., etc. Preferable examples of the reactive derivatives at carboxylic acid of Compound (VI) include those mentioned for Compound (III).

[0060] Examples of the esterifying agent used in the esterification reaction include a compound of the formula:



wherein R^8 has the meaning given above, R^{8a} is a group removed a hydrogen atom from R^8 , X^1 is hydroxy or a halogen. Preferable examples of the halogen include chlorine, bromine, iodine and fluorine.

[0061] In case that a sulfuric acid ester and an alkyl halide are used as the esterifying agent, while the reaction is usually carried out in a solvent such as water, acetone, methylene chloride, ethanol, ether, dimethylformamide, etc., the reaction can be carried out in any solvent which does not interfere with the reaction. The reaction is preferably carried out in the presence of the inorganic base or the organic base mentioned above.

The reaction temperature is not limiting but the reaction is usually carried out under cooling or under heating which is not higher than the boiling point of the solvent used.

[0062] In case that a diazo compound is used as the esterifying agent, the reaction is usually carried out in the presence of ether, tetrahydrofuran, etc., the reaction temperature is not limiting but the reaction is usually carried out under cooling or at an ambient temperature.

[0063] Preferable examples of the salts of Compound (VII) include, an acid addition salt such an organic acid salt as acetic acid salt, maleic acid salt, tartaric acid salt, benzenesulfonic acid salt, toluenesulfonic acid salt, etc., such inorganic acid salt as hydrochloric acid salt, hydrobromic acid salt, sulfuric acid salt, phosphoric acid salt, etc.

Productions B and D

[0064] A compound of the formula (III), its reactive derivatives at the carboxylic acid or its salt (hereinafter referred to as Compound (III)) and a compound of the formula (IIIa), its reactive derivatives at the carboxylic acid or its salt (hereinafter referred to as Compound (IIIa)) can be produced by introducing a phosphono group to the amino group of Compound (VI) and Compound (VII), respectively. Preferable examples of the reactive derivatives at the carboxylic acid of Compound (VI) and Compound (VII) include those mentioned for Compound (III). Examples of the introducing agents to be used in the introduction reaction include, an phosphorus halide such as phosphorus trichloride, phosphorus pentachloride, etc., phosphorus oxychloride, etc. The reaction is usually carried out in a solvent such as a halogenated alkylene (e.g. methylene chloride, ethylene chloride, etc.) toluene, ethyl acetate, tetrahydrofuran, etc.

[0065] In this reaction, the reaction mixture containing Compound (II) or Compound (IIIa), wherein R^1 is a dihalophosphoryl group, which is obtained by reacting Compound (VI) or Compound (VII) with the above mentioned introducing agent such as a phosphorous halide, can be treated with water to give a reaction mixture containing Compound (III) or (IIIa) wherein R^1 is a phosphono group, or can be treated with an alcohol such an alkanol as methanol, ethanol, etc. to give a reaction mixture containing Compound (III) or Compound (IIIa) wherein R^0 is an esterified phosphono group.

[0066] The reaction product (III) or (IIIa) wherein R^0 is a dihalophosphoryl group can be isolated from the above mentioned reaction mixture by means of a conventional isolation method. The product can be used in the following reaction.

The reaction includes changing Compound (IIIa) to the reactive derivative at the carboxylic group.

Production C


[0067] Compound (III) can be produced by subjecting Compound (IIIa) to deesterification reaction. Preferable examples of the salt of Compound (III) include those enumerated for Compound (VI). The reaction is carried out by a conventional method such as hydrolysis, reduction, etc. The hydrolysis is preferably carried out in the presence of a base or an acid. Preferable examples of the base include an inorganic base and an organic base such as an alkali metal (e.g. sodium, potassium, etc.), an alkaline earth metal (e.g. magnesium, calcium, etc.), hydroxide, carbonate, bicarbonate of the above mentioned metal, an trialkylamine (e.g. trimethylamine, triethylamine, etc.), picoline, 1,5-di-azabicyclo[4.3.0]nona-5-ene, 1,4-di-azabicyclo[2,2,2]octane, 1,8-di-azabicyclo[5.4.0]undecane, etc.

[0068] Preferable examples of the acid include an organic acid such as formic acid, acetic acid, propionic acid, trifluoroacetic acid, etc., an inorganic acid such as hydrochloric acid, hydrobromic acid, sulfuric acid, etc. Trifluoroacetic acid is preferably used in the presence of a -carbocation stabilizing agent such as anisole, etc.

[0069] While the reaction is usually carried out in water, methylene chloride, tetrahydrofuran, an alcohol (e.g. methanol, ethanol, etc.) or a mixture thereof, a solvent which does not interfere with the reaction may be used. A liquid base or an acid may also be used as a solvent. The reaction temperature is not limiting and the reaction is carried out usually under cooling or under mild conditions like slight heating.

[0070] The reduction can be applied to deprotection of a protecting group of the ester, such as 4-nitrobenzyl, 2-iodoethyl, 2,2,2-trichloro ethyl, etc. As the method of the reduction which is applied to the deesterification reaction, there may be mentioned a method using a metal such as zinc, zinc amalgam, etc., or a chromium compound salt such as chromous chloride salt, chromous acetate salt, etc., in combination with an organic or inorganic salt such as acetic acid, propionic acid, hydrochloric acid, etc., and a catalytic reduction method using a metal catalyst such as palladium-carbon, etc.

[0071] The production of a starting compound that is a compound of the formula (III d) or its reactive derivative (hereinafter referred to as Compound (III d)) is as follows.



[wherein R^{0a} is a dihalophosphoryl group, R^{1a} is a phosphono group which may be protected. (The definition of R^{1a} is the same as that of R^1 , but R^{1a} and R^1 may be the same as or different from each other.

Production E

[0072] A compound of the formula (III b), its reactive derivative or its salt (hereinafter referred to as Compound (III b)) can be produced by subjecting Compound (VII) to a reaction in which a dihalophosphoryl group is introduced to the amino group of Compound (VII). The reaction can be carried out in a similar manner to Production B or Production D.

Production F

[0073] A compound of the formula (III c), its reactive derivative or its salt (hereinafter referred to as Compound (III c)) can be produced by subjecting Compound (III b) to a reaction in which the dihalophosphoryl group is converted to a phosphono group other than dihalophosphoryl group. The reaction can be carried out by subjecting Compound (III b) to an esterification reaction and/or amidation reaction.

[0074] The esterification reaction is carried out by reacting Compound (III b) with an alcohol. Preferable examples of the alcohol include methanol, ethanol, propanol, butanol, etc. The amidation reaction can be carried out by reacting Compound (III b) with an amine. Preferable examples of the amine include ammonia, a primary amine such as methylamine, ethylamine, etc., a secondary amine such as morpholine, dimethylamine, etc., etc.

[0075] While the esterification reaction or amidation reaction is usually carried out in a solvent such as a halogenated alkylene (e.g. methylene chloride, ethylene chloride, etc.), tetrahydrofuran, water, etc., it can be carried out in any solvent which does not interfere with the reaction. The reaction temperature is not limiting though the reaction is carried out usually under cooling or an ambient temperature.

Production G

[0076] Compound (III d) can be produced by subjecting Compound (III c) to deesterification reaction. The reaction is carried out in a similar manner to that of Production C.

[0077] In the reactions mentioned above, when the starting compound has an amino group and/or a carboxyl group, these groups may be protected by a protecting group which is conventionally used in the field of peptide chemistry, and

the protecting group may be removed after the reaction.

[0078] Examples of the protecting group for the amino group include, for example, a formyl group, a C₁₋₆alkyl-carbonyl group (for example, acetyl, ethylcarbonyl, etc.), a benzyl group, a tert-butyloxycarbonyl group, a benzyloxycarbonyl group, a 9-fluorenyl methyloxycarbonyl group, an allyloxycarbonyl group, a phenylcarbonyl group, a C₁₋₆alkyl-carbonyl group (for example, methoxycarbonyl, ethoxycarbonyl, etc.), a C₇₋₁₀aralkyl-carbonyl group (for example, benzylcarbonyl, etc.), a trityl group, phthaloyl group, a N,N-dimethylaminomethylene group, etc. These groups may be substituted by 1 to 3 of a halogen atom (for example, fluorine, chlorine, bromine, etc.), a nitro group, etc.

Examples of the protecting group for the carboxyl group include, for example, a C₁₋₆alkyl group (for example, methyl, ethyl, propyl, isopropyl, butyl, tert-butyl, etc.), a phenyl group, a silyl group, a benzyl group, an allyl group, etc. These groups may be substituted by one to three of a halogen atom (for example, fluorine, chlorine, bromine, etc.), a nitro group, etc.

[0079] Examples of the protecting group for the hydroxy include, for example, a methoxy methyl group, an allyl group, a tert-butyl group, a C₇₋₁₀aralkyl group (for example, benzyl, etc.), formyl group, a C₁₋₆alkyl-carbonyl group (for example, acetyl, ethylcarbonyl, etc.), a benzoyl group, a C₇₋₁₀aralkyl-carbonyl group (for example, benzylcarbonyl, etc.), a pyranyl group, a furanyl group, a tri-alkyl silyl group, etc. These groups may be substituted by 1 to three of a halogen atom (for example, fluorine, chlorine, bromine, etc.), a C₁₋₆alkyl group (for example, methyl, ethyl, propyl, isopropyl, butyl, tert-butyl, etc.), a phenyl group, a C₇₋₁₀aralkyl group (for example, benzyl, etc.), a nitro group, etc.

[0080] As the method for the deprotection of these protecting group, a method using, for example, an acid, a base, reduction, ultraviolet ray, hydrazine, phenyl hydrazine, sodium N-methyl di-thiocarbamate, tetrabutyl ammonium fluoride, palladium acetate, etc. can be applied, using known or similar methods. When a compound is obtained as a free form in each reaction process, the compound can be converted to its salt, and when the compound is obtained as a salt, it can be converted to its free form or to another salt.

[0081] Compound (I) thus obtained can be isolated from the reaction mixture and purified by a known procedure such as phase transfer, concentration, solvent extraction, fractional distillation, crystallization, recrystallization, chromatography, etc. When Compound (I) of the present invention exists in the form of diastereomer, conformer, etc., Compound (I) can be isolated and purified by an isolation procedure or a purification procedure mentioned above, if desirable. When Compound (I) is a racemate, (d)-form and (l)-form of Compound (I) can be isolated by a usual optical resolution procedure.

[0082] Compound (I) of the present invention has a solubility higher than that of the corresponding compound having an aminothiazolyl group wherein the amino group is free form (that is Compound (I) wherein R¹ is an amino group), and Compound (I) of the present invention in vivo, gives a corresponding compound having an aminothiazolyl group by removing group R¹. Further Compound (I) is superior in an anti-bacterial activity to a compound having aminothiazolyl group.

[0083] The compound (I) of this invention has broad spectrum antibacterial activity and low toxicity, and can be used safely for prophylaxis and therapy of various diseases, in man and mammals (e.g. mouse, rat, rabbit, dog, cat, cow and pig), caused by pathogenic bacteria, for example, respiratory infection and urinary tract infection. Characteristic features of the antibacterial spectrum of the antibacterial compound. (I) are as follows, among others :

- (1) showing a remarkably high activity against a variety of Gram-negative bacteria,
- (2) having high activities against Gram-positive bacteria (e.g. *Staphylococcus aureus* and *Corynebacterium diphtheriae*),
- (3) having high activities against methicillin-resistant *Staphylococcus aureus* (MRSA), and
- (4) having high activities also against a number of β -lactamase-producing Gram-negative bacteria (e.g. genera *Escherichia*, *Enterobacter*, *Serratia* and *Proteus*).

The anti-bacterial compound (I) of the present invention has superior stability and effectiveness of anti-bacterial activity in comparison with Compound (V).

[0084] The compound (I) of this invention can be administered, like known penicillin preparations or cephalosporin preparations, non-orally or orally as injectable preparations, capsules, tablets or granular preparations (injectable preparations are especially preferable). The daily dose ranges from 0.5 to 80 mg, preferably from 2 to 40 mg relative to 1 kg of the body weight of a man or an animal infected with pathogenic bacteria as described above, which may be administered in two or three divided doses.

[0085] Though the drug of the present invention may comprise only Compound (I) itself, it is usually prepared by a conventional manner by using a proper amount of pharmaceutically acceptable carriers, diluents and bulking agents, etc. which are selected from excipients (for example, calcium carbonate, kaolin, sodium hydrogencarbonate, lactose, D-mannitol, starch, crystalline cellulose, talc, fine granulated sugar, porous substance, etc.), binders (for example, dextrin, gums, α -starch, gelatine, hydroxypropylcellulose, hydroxy propyl methyl cellulose, pullulan, etc.), thickeners (for example, a natural gum, a cellulose derivative, an acrylic acid derivative, etc.), disintegrators (for example, carboxymethylcellulose calcium, crosscarmellose sodium, crospovidone, a low-substituted hydroxypropylcellulose, partly pregelati-

nized starch, etc.), solvents (for example, water for injection, alcohol, propyleneglycol, Macrogol, sesame oil, corn oil, etc.), dispersants (for example, Tween 80, HCO60, poly ethylene glycol, carboxymethylcellulose, sodium alginate, etc.), solubilizing agents (for example, polyethylene glycol, propyleneglycol, D-mannitol, benzoic acid benzyl, ethanol, tris amino methane, tri-ethanolamine, sodium carbonate, citric acid sodium, etc.), suspending agents (for example, stearyl triethanolamine, sodium laurylsulfate, benzalkonium chloride, polyvinylalcohol, polyvinylpyrrolidone, hydroxymethylcellulose, etc.), soothing agents (for example, benzyl alcohol, etc.), isotonic agents (for example, sodium chloride, glycerin, etc.), buffer agents (for example, phosphoric acid salt, acetic acid salt, carbonic acid salt, citric acid salt, etc.), lubricants (for example, magnesium stearate, calcium stearate, talc, starch, sodium benzoate, etc.), coloring agents (for example, tar pigment, caramel, ferric oxide, titanium oxide, riboflavins, etc.), corrigents (for example, a sweetening agent, a perfume, etc.), stabilizers (for example, sodium sulfite, ascorbic acid, etc.) and preservatives (for example, paraben, sorbic acid, etc.), etc.

[0086] The pharmaceutical composition of the present invention which may contain pharmaceutically acceptable carriers, diluents, bulking agents, etc., mentioned above contains an effective amount of Compound (I) of the present invention for the treatment and prevention. The amount of Compound (I) contained in the pharmaceutical preparation of the present invention is usually 0.1 to 100 weight % of the pharmaceutical preparation. The pharmaceutical preparation of the present invention may contain pharmaceutically active ingredients other than Compound (I) (e.g. antitumor agents, etc., mentioned below). The amount of the pharmaceutically active ingredient other than Compound (I) is not limited as long as the aim of the present invention can be achieved. Examples of the preparation includes tablets (including a sugar-coated tablet, a film-coated tablet), pills, capsules (including microcapsule), granules, fine granules, powders, drop infusions, syrups, emulsions, suspensions, injections, inhalations, ointments, suppositories, troches, cataplasms, sustained release preparations, etc. These preparation can be prepared by a conventional method (e.g., a method shown in The Pharmacopoeia of Japan The Twelfth Edition, etc.).

[0087] As carriers for injectable preparations, use is made of, for example, distilled water or a physiological saline solution.

Carriers for capsules, powdery preparations, granular preparations or tablets are used as a mixture with known pharmaceutically acceptable excipients (e.g. starch, maltose, sucrose, calcium carbonate or calcium phosphate), binders (e.g. starch, gum arabic, carboxymethyl cellulose, hydroxypropyl cellulose or crystalline cellulose), lubricants (e.g. magnesium stearate or talc) and disintegrants (e.g. carboxymethyl calcium and talc).

[0088] The compound (I) of this invention can be administered, like known penicillin preparations or cephalosporin preparations, non-orally or orally as injectable preparations, capsules, tablets or granular preparations (injectable preparations are especially preferable). The daily dose ranges from 0.5 to 80 mg, preferably from 2 to 40 mg relative to 1 kg of the body weight of a man or an animal infected with pathogenic bacteria as described above, which may be administered in two to three divided doses.

[0089] As carriers for injectable preparations, use is made of, for example, distilled water or a physiological saline solution.

Carriers for capsules, powdery preparations, granular preparations or tablets are used as a mixture with known pharmaceutically acceptable excipients (e.g. starch, maltose, sucrose, calcium carbonate or calcium phosphate), binders (e.g. starch, gum arabic, carboxymethyl cellulose, hydroxypropyl cellulose or crystalline cellulose), lubricants (e.g. magnesium stearate or talc) and disintegrants (e.g. carboxymethyl calcium and talc). Incidentally, the medicinal composition and antibacterial composition employed in the present specification may contain the compound (I) alone, or contain, among others, such carriers as set forth above, or contain a proper amount of any other adequate antibacterial compound.

[0090] The present invention will be illustrated in further detail in the following Working Examples, which are mere examples and do not limit this invention, and may be modified within the range not deviating from the scope of this invention.

[0091] Elutions in the column chromatography conducted in Working Examples were carried out while monitoring with TLC (Thin Layer Chromatography). In the TLC monitoring, as the TLC plate, use was made of 60F₂₅₄ manufactured by Merck & Co., Inc., as the developing solvent, use was made of the same solvent as employed for eluting in the column chromatography, and the detection was conducted with a UV detector. The silica gel (70 to 230 mesh) for the column was Kieselgel 60 manufactured by Merck & Co. Inc. ODS-AM is produced by YMC Co. Ltd., Dowex50W is produced by The Dow Chemical Company and Diaion HP-20SS and SP-207 are produced by Mitsubishi Chemical Industries, Ltd.

[0092] NMR spectra were measured using tetramethylsilane as an internal or external standard with a spectrometer Gemini 200 and all delta values were expressed in ppm. The value shown in () for a mixed solvent is a mixing ratio in volume of constituent solvents. The percent (%) for a solution indicates the number of grams in 100 ml of the solution. And, the symbols in Reference Examples and Working Examples have the following meaning.

s : singlet
d : doublet
t : triplet

q : quartet
 ABq : AB type quartet
 dd : double doublet
 m : multiple
 5 bs : broad singlet
 J : coupling constant

Working Example 1

10 7 β -[2(Z)-Ethoxyimino-2-(5-phosphonoamino-1,2,4-thiadiazol-3-yl)acetamido]-3-[4-(1-methyl-4-pyridinio)-2-thiazolylthio]-3-cephem-4-carboxylate

[0093] Under ice-cooling, the pH of a solution of 7 β -amino-3-[4-(1-methyl-4-pyridinio)-2-thiazolylthio]-3-cephem-4-carboxylate hydrochloride (1.55g) in a mixture of THF (50ml) and H₂O (50ml) was adjusted to 7.4 with 0.6M NaHCO₃.
 15 To the solution was added portionwise 2-(5-dichlorophosphorylamino-1,2,4-thiadiazol-3-yl)-2(Z)-ethoxyiminoacetyl chloride (3.69g), and the mixture was stirred at 5°C for 10 minutes while maintaining the pH to 7.2 to 7.3 by addition of 0.6M NaHCO₃. A solution of sodium acetate (861mg) in H₂O (10ml) was poured into the reaction mixture, and the resulting mixture was stirred at room temperature for 2.5 hours. During the stirring, the pH of the mixture was maintained above 4.5 by the occasional addition of 0.6M NaHCO₃ (total volume 56ml). After the pH of the mixture was adjusted to 3.0 with
 20 1N HCl (4ml), the reaction mixture was concentrated under reduced pressure. The concentrate was diluted with H₂O (800ml) and purified by MCI gel HP-20SS column chromatography (500ml: eluents = H₂O 1.5L, 10% aq EtOH 0.5L, 20% aq EtOH 1.5L).

The fractions containing the desired compound were concentrated under reduced pressure, and the concentrate was lyophilized to give the crude titled compound (1.64g).

25 [0094] ¹H NMR (D₂O) δ : 1.33 (3H,t, $J=7.2$ Hz), 3.56, 3.94 (2H,ABq, $J=17.2$ Hz), 4.34 (3H,s), 4.35 (2H,q, $J=7.2$ Hz), 5.38 (1H, d, $J=5$ Hz), 5.90 (1H, d, $J=5$ Hz), 8.34, 8.72 (each 2H, d, $J=6.6$ Hz), 8.51 (1H,s); IR (KBr, cm⁻¹): 3055, 1778, 1682, 1643, 1520, 1385, 1190, 1038.

Working Example 2

30 7 β -[2(Z)-Ethoxyimino-2-(5-phosphonoamino-1,2,4-thiadiazol-3-yl)acetamido]-3-[4-(1-methyl-4-pyridinio)-2-thiazolylthio]-3-cephem-4-carboxylate

[0095] The crude lyophilized compound (1.54g) obtained in Working Example 1 was dissolved in a solution of NaHCO₃ (378mg) in H₂O (16ml). The solution was subjected to ODS-AM column chromatography (450ml: eluents = 1N HCl 4.5ml, H₂O 1.0L, 5% aq acetonitrile 0.5L, 20% aq acetonitrile 0.25L). The fractions containing the desired compound were concentrated under reduced pressure, and the concentrate was lyophilized to give the titled compound (431mg).

[0096] Anal/Calcd for C₂₂H₂₁N₈O₈PS₄·2.0H₂O: C, 36.66; H, 3.50; N, 15.55. Found: C, 36.70; H, 3.94; N, 15.53.

40 Working Example 3

7 β -[2(Z)-Fluoromethoxyimino-2-(5-phosphonoamino-1,2,4-thiadiazol-3-yl)acetamidol-3-[4-(1-methyl-4-pyridinio)-2-thiazolylthio]-3-cephem-4-carboxylate

45 [0097] Under ice-cooling, the pH of a solution of 7 β -amino-3-[4-(1-methyl-4-pyridinio)-2-thiazolylthio]-3-cephem-4-carboxylate hydrochloride (1.42g) in a mixture of THF (50ml) and H₂O (50ml) was adjusted to 7.5 with 0.6M NaHCO₃ (12ml). To the solution was added portionwise 2-(5-dichlorophosphorylamino-1,2,4-thiadiazol-3-yl)-2(Z)-fluoromethoxyiminoacetyl chloride (3.41g), and the mixture was stirred at 5°C for 10 minutes while maintaining the pH to 7.2 to 7.5 by addition of 0.6M NaHCO₃ (24ml).

50 A solution of sodium acetate (787mg) in H₂O (20ml) was poured into the reaction mixture, and the resulting mixture was stirred at room temperature for 3 hours. After the pH of the mixture was adjusted to 3.0 with 1N HCl (3.4ml), the reaction mixture was concentrated under reduced pressure. The concentrate was diluted with H₂O (750ml) and purified by MCI gel HP-20SS column chromatography (500ml: eluents = H₂O 1.5L, 10% aq EtOH 0.5L, 20% aq EtOH 1.5L). The fractions containing the desired compound were concentrated under reduced pressure, and the concentrate was lyophilized to
 55 give the crude titled compound (0.96g).

[0098] ¹H NMR (D₂O) δ : 3.57, 3.94 (2H, ABq, $J=17.4$ Hz), 4.34 (3H,s), 5.40 (1H,d, $J=4.8$ Hz), 5.85 (2H,d, $J=5.5$ Hz), 5.93 (1H, d, $J=4.8$ Hz), 8.34, 8.72 (each 2H,d, $J=6.4$ Hz), 8.51 (1H,s); IR (KBr, cm⁻¹): 3055, 1781, 1677, 1642, 1523, 1364, 1189, 1071.

Working Example 4

7β-[2(Z)-Fluoromethoxyimino-2-(5-phosphonoamino-1,2,4-thiadiazol-3-yl)acetamido]-3-[4-(1-methyl-4-pyridinio)-2-thiazolythio]-3-cephem-4-carboxylate

5

[0099] The crude lyophilized compound (0.96g) obtained in Working Example 3 was dissolved in a solution of NaHCO₃ (234mg) in H₂O (15ml). The solution was subjected to ODS-AM column chromatography (450ml: eluents = 1N HCl 3.06ml, H₂O 1.0L, 20% aq acetonitrile 0.25L, 30% aq acetonitrile 0.6L). The fractions containing the desired compound were concentrated under reduced pressure, and the concentrate was lyophilized to give the titled compound (600mg).

10

[0100] Anal Calcd for C₂₁H₁₈N₈O₈PS₄·2.0H₂O: C, 34.81; H, 3.06; N, 15.46; P, 4.27. Found: C, 34.84; H, 3.28; N, 15.43; P, 4.18.

Working Example 5

15

7β-[2(Z)-Ethoxyimino-2-(5-phosphonoamino-1,2,4-thiadiazol-3-yl)acetamido]-3-[4-(1-methyl-4-pyridinio)-2-thiazolythio]-3-cephem-4-carboxylate

20

[0101] Under ice-cooling, 0.6M NaHCO₃ (34ml) was added to a solution of 7β-amino-3-[4-(1-methyl-4-pyridinio)-2-thiazolythio]-3-cephem-4-carboxylate hydrochloride (3.0g) in a mixture of THF (150ml) and H₂O (150ml). To the solution were added portionwise 2-(5-dichlorophosphorylamino-1,2,4-thiadiazol-3-yl)-2(Z)-ethoxyiminoacetyl chloride (4.76g) and 0.6M NaHCO₃ (23ml) successively. The resulting mixture was stirred at 5°C for 15 minutes and then at room temperature for 2 hours. Under ice-cooling, the pH of the reaction mixture was adjusted to 5.0 with 1N NaOH, and the mixture was concentrated under reduced pressure. The concentrate was diluted with H₂O (2.5L), and the pH of the solution was adjusted to 3.0 with 1N HCl. The mixture was purified by MCI gel SP-207 column chromatography (750ml: eluents = H₂O 4L, 15% aq EtOH 6L). The fractions containing the desired compound were concentrated under reduced pressure, and the concentrate was lyophilized to give the crude titled compound (2.6g).

25

[0102] ¹H NMR (DMSO-*d*₆) δ: 1.23 (3H, t, *J*=7Hz), 3.56, 3.94 (2H, ABq, *J*=17Hz), 4.17 (2H, q, *J*=7Hz), 4.33 (3H, s), 5.30 (1H, d, *J*=5Hz), 5.90 (1H, dd, *J*=5&8.8Hz), 8.50, 8.97 (each 2H, d, *J*=6.4Hz), 8.98 (1H, s), 9.22 (1H, m), 9.69 (1H, d, *J*=8.8Hz).

30

Working Example 6

35

7β-[2(Z)-Ethoxyimino-2-(5-phosphonoamino-1,2,4-thiadiazol-3-yl)acetamido]-3-[4-(1-methyl-4-pyridinio)-2-thiazolythio]-3-cephem-4-carboxylate

40

[0103] The crude lyophilized compound (1.24g) obtained in Working Example 5 was dissolved in H₂O (13ml) containing 1N NaOH (3.24ml). The solution was subjected to ODS-AM column chromatography (450ml: eluents = H₂O). The fractions containing sodium salt form of the desired compound were passed through Dowex 50×8 column (H form, 20 to 50mesh, 100ml). The eluent was concentrated under reduced pressure, and the concentrate was lyophilized to give the titled compound (377mg).

[0104] Anal Calcd for C₂₂H₂₁N₈O₈PS₄·3.5H₂O: C, 35.29; H, 3.77; N, 14.97. Found: C, 35.26; H, 3.45; N, 14.99.

[0105] ¹H NMR (DMSO-*d*₆) δ: 1.24 (3H, t, *J*=7Hz), 3.54, 3.94 (2H, ABq, *J*=17Hz), 4.20 (2H, q, *J*=7Hz), 4.33 (3H, s), 5.30 (1H, d, *J*=5.2Hz), 5.89 (1H, dd, *J*=5.2&8.6Hz), 8.51, 8.98 (each 2H, d, *J*=5.6Hz), 8.98 (1H, s), 9.17 (1H, m), 9.69 (1H, d, *J*=8.6Hz).

45

Working Example 7

50

7β-[2(Z)-Ethoxyimino-2-(5-phosphonoamino-1,2,4-thiadiazol-3-yl)acetamido]-3-[4-(1-methyl-4-pyridinio)-2-thiazolythio]-3-cephem-4-carboxylate

55

[0106] Trimethylsilylacetamide (919mg) was added to a suspension of 7β-amino-3-[4-(1-methyl-4-pyridinio)-2-thiazolythio]-3-cephem-4-carboxylate hydrochloride (240mg) in dichloromethane (4ml), and the mixture was stirred at room temperature for 40 minutes. To the mixture was added portionwise 2-(5-dichlorophosphorylamino-1,2,4-thiadiazol-3-yl)-2(Z)-ethoxyiminoacetyl chloride (351mg) under cooling at -15°C, and the mixture was stirred at -15 to -5°C for 1 hour. After concentration of the reaction mixture under reduced pressure, the concentrate was diluted with H₂O (150ml). Under ice-cooling, the pH of the mixture was adjusted to 5.0 with 1N NaOH. The mixture was diluted with H₂O (200ml), and the pH of the mixture was adjusted to 3.0 with 1N HCl. The mixture was purified by MCI gel SP-207 column chromatography (180ml: eluents = H₂O 0.5L, 15% aq EtOH 0.6L). The fractions containing the desired compound were concentrated

under reduced pressure, and the concentrate was lyophilized to give the crude titled compound (100mg).

[0107] $^1\text{H NMR}$ ($\text{DMSO}-d_6$) δ : 1.23 (3H,t, $J=7\text{Hz}$), 3.56, 3.94 (2H, ABq, $J=17\text{Hz}$), 4.17 (2H,q, $J=7\text{Hz}$), 4.33 (3H,s), 5.30 (1H, d, $J=5\text{Hz}$), 5.90 (1H, dd, $J=5\&8.8\text{Hz}$), 8.50, 8.97 (each 2H,d, $J=6.4\text{Hz}$), 8.98 (1H,s), 9.22 (1H,m), 9.69 (1H,d, $J=8.8\text{Hz}$).

5 Working Example 8

[0108] The lyophilized 7β -[2(Z)-ethoxyimino-2-(5-phosphonoamino-1,2,4-thiadiazol-3-yl)acetamidol-3-[4-(1-methyl-4-pyridinio)-2-thiazolythio]-3-cephem-4-carboxylate (300mg equivalent), obtained in Working Example 6, was dissolved in saline, the pH was adjusted to 6.0, and saline was added to make the total volume 5ml (60mg equivalent/ml).

10

Experiment 1

[0109] The lyophilized 7β -[2(Z)-ethoxyimino-2-(5-phosphonoamino-1,2,4-thiadiazol-3-yl)acetamidol-3-[4-(1-methyl-4-pyridinio)-2-thiazolythio]-3-cephem-4-carboxylate, obtained in Working Example 6, was dissolved in mouse plasma to prepare 10mg equivalent/ml solution. After incubation at 37°C , the transformation rate into 7β -[2(Z)-ethoxyimino-2-(5-amino-1,2,4-thiadiazol-3-yl)acetamido]-3-[4-(1-methyl-4-pyridinio)-2-thiazolythio]-3-cephem-4-carboxylate (amino form) was measured. The transformation rates in 30 minutes and 1 hour were as follows:

15

30 minutes	35%
1 hour	62%

20


INDUSTRIAL APPLICABILITY

[0110] The cephem compound (I) has a broad antibacterial spectrum and an excellent antibacterial activity against Gram-negative bacteria and Gram-positive bacteria including *Staphylococcus aureus* and MRSA, and its useful for treatment or prevention of infectious diseases caused by these bacteria. And the compound (I) has a relatively high solubility in water, and can be advantageously used as injection.

25

1. A compound of the formula:

30



35

40

wherein R^1 is a phosphono group or a group convertible to a phosphono group; R^2 is a hydrogen atom or a group having a linkage through a carbon atom; each of Q and X is a nitrogen atom or CH ;

45

Y is S , O or CH_2 ; n is 0 or 1; one of R^3 and R^4 is a pyridinium group which may be substituted and the other is a hydrogen atom

or a hydrocarbon group which may be substituted, or R^3 and R^4 taken together may form a quaternalized nitrogen-containing heterocyclic ring which may be substituted, salt or ester thereof.

2. A compound as item (1), wherein R^1 is a phosphono group which may be protected.

50

3. A compound as item (1), wherein R^1 is phosphono, dialkoxy-phosphoryl, O-alkyl-phosphono, diaminophosphoryl, (amino)(hydroxy)phosphoryl, (alkoxy)(morpholino)phosphoryl or dihalophosphoryl.

4. A compound as item (1), wherein R^1 is a phosphono group.

5. A compound as item (1), wherein Y is S .


6. A compound as item (1), wherein R^2 is a C_{1-6} alkyl group which may be substituted or a C_{3-5} cycloalkyl group.

55

7. A compound as item (1), wherein R^3 is a pyridinium group which may be substituted and R^4 is a hydrogen atom.

8. A compound as item (1), wherein the group of the formula:


5



10

is


15



20

or

25



30

wherein R⁵ is a hydrocarbon group which may be substituted.

35

9. A compound as item (1), wherein Q is a nitrogen atom.

10. A compound as item (1) wherein X is a nitrogen atom.

11. A compound according to the above (1), wherein n is 0.


12. A compound according to the above (1), which is 7β-[2(Z)-ethoxyimino-2-(5-phosphonoamino-1,2,4-thiadiazole-3-yl)acetamido]-3-[4-(1-methyl-4-pyridinio)-2-thiazolythio]-3-cephem-4-carboxylate, its ester or its salt.

40

13. A compound according to the above (1), which is 7β-[2(Z)-fluoromethoxyimino-2-(5-phosphonoamino-1,2,4-thiadiazole-3-yl)acetamido]-3-[4-(1-methyl-4-pyridinio)-2-thiazolythio]-3-cephem-4-carboxylate, its ester or its salt.

14. A method for producing a compound as item (1), which comprises reacting a compound of the formula:


45



50


wherein each symbol has the meaning given above, its ester or its salt, with a compound of the formula:

55



10 wherein each symbol has the meaning given above, its salt or its reactive derivative, if necessary, followed by converting R¹ to a phosphono group.

15 15. A method for producing a compound as item (1), which comprises subjecting a compound of the formula:



25 wherein one of R^{3'} and R^{4'} is a pyridyl group which may be substituted, and the other is a hydrogen atom or a hydrocarbon group which may be substituted, or R^{3'} and R^{4'}, taken together, represent a nitrogen-containing heterocyclic ring which may be substituted, and the other symbols have the meanings given above, its ester or its salt to the reaction in which quaternized-ammonium is formed, if necessary, followed by converting R¹ to a phosphono group.

30 16. A pharmaceutical composition containing the compound as item (1).

17. A pharmaceutical composition containing the compound shown in item (1) and at least one of pharmaceutically acceptable carriers, diluents and bulking agents.

18. A pharmaceutical composition as item (16), which is an anti-bacterial composition.

19. A pharmaceutical composition as item (16), which is an anti-MRSA agent.

35 20. A pharmaceutical composition as item (16), which is an injectable composition.

21. Use of the compound as item (1) for producing a pharmaceutical composition.

22. Use as item (21), wherein the pharmaceutical composition is an antibacterial agent.

23. Use as item (21), wherein the pharmaceutical composition is an anti-MRSA agent.

24. Use as item (21), wherein the pharmaceutical composition is an injectable composition.

40 25. A method for treating a bacterial infection which comprises administering an effective amount of a compound as claimed in claim 1 to a patient suffering from the bacterial infection.

26. A method for treating a bacterial infection which comprises administering an effective amount of a compound as item (1)

45 together with at least one of pharmaceutically acceptable carriers, diluents and excipients to a patient suffering from the bacterial infection.

27. A method as item (25), wherein the bacterial infection is a MRSA infection.

28. A method as item (25), wherein the compound is administered by injection.

50 **Claims**

1. 7β-[2(Z)-ethoxyimino-2-(5-phosphonoamino-1,2,4-thiazole-3-yl)acetamido]-3-[4-(1-methyl-4-pyridinio)-2-thiazolylthio]-3-cephem-4-carboxylate, its ester or its salt.

55 2. The compound as defined in claim 1 for use as bactericide.

3. The compound of claim 2 for use as bactericide against methicillin-resistant *Staphylococcus aureus* (MRSA).

EP 2 080 765 A1

4. A pharmaceutical composition containing the compound as defined in claim 1.
5. The pharmaceutical composition of claim 2 further containing at least one of pharmaceutically acceptable carriers, diluents and bulking agents.
- 5 6. The pharmaceutical composition as defined in claim 4 or 5 for use as bactericide.
7. The pharmaceutical composition of claim 6 for use as bactericide against methicillin-resistant *Staphylococcus aureus* (MRSA).
- 10 8. The pharmaceutical composition of any one of claims 4 to 7 in injectionable form.
9. Use of the compound as defined in claim 1 for producing a pharmaceutical composition.
- 15 10. The use of claim 9 for producing an injectionable pharmaceutical composition.

20

25

30

35

40

45

50

55



EUROPEAN SEARCH REPORT

Application Number
EP 09 15 8866

DOCUMENTS CONSIDERED TO BE RELEVANT			
Category	Citation of document with indication, where appropriate, of relevant passages	Relevant to claim	CLASSIFICATION OF THE APPLICATION (IPC)
P,X	PATENT ABSTRACTS OF JAPAN vol. 1999, no. 01, 29 January 1999 (1999-01-29) & JP 10 265488 A (TAKEDA CHEM IND LTD), 6 October 1998 (1998-10-06) * insertion of -CH=CH- spacer in 3-position * * abstract *	1-10	INV. C07F9/6561
X	----- PATENT ABSTRACTS OF JAPAN vol. 1997, no. 08, 29 August 1997 (1997-08-29) & JP 09 100283 A (TAKEDA CHEM IND LTD), 15 April 1997 (1997-04-15) * compare the definitions of n=0, R1, R3 and R4 * * abstract *	1-10	
Y	----- EP 0 099 553 A (FUJISAWA PHARMACEUTICAL CO) 1 February 1984 (1984-02-01) * the whole document *	1-10	TECHNICAL FIELDS SEARCHED (IPC)
Y	& PATENT ABSTRACTS OF JAPAN vol. 8, no. 118 (C-226), 31 May 1984 (1984-05-31) & JP 59 031791 A (FUJISAWA YAKUHIN KOGYO), 20 February 1984 (1984-02-20) * compare the definition of R1 * * abstract *	1-10	C07F
Y	----- EP 0 007 470 A (FUJISAWA PHARMACEUTICAL CO) 6 February 1980 (1980-02-06) * compare the definitions of R1 and R4 * * the whole document * ----- -/--	1-10	
The present search report has been drawn up for all claims			
Place of search Munich		Date of completion of the search 4 June 2009	Examiner Stellmach, Joachim
<p>CATEGORY OF CITED DOCUMENTS</p> <p>X: particularly relevant if taken alone Y: particularly relevant if combined with another document of the same category A: technological background O: non-written disclosure P: intermediate document</p> <p>T: theory or principle underlying the invention E: earlier patent document, but published on, or after the filing date D: document cited in the application L: document cited for other reasons &: member of the same patent family, corresponding document</p>			

3
EPO FORM 1503 03 82 (P04C01)



EUROPEAN SEARCH REPORT

Application Number
EP 09 15 8866

DOCUMENTS CONSIDERED TO BE RELEVANT			
Category	Citation of document with indication, where appropriate, of relevant passages	Relevant to claim	CLASSIFICATION OF THE APPLICATION (IPC)
Y	PATENT ABSTRACTS OF JAPAN vol. 012, no. 117 (C-487), 13 April 1988 (1988-04-13) & JP 62 238291 A (FUJISAWA PHARMACEUT CO LTD), 19 October 1987 (1987-10-19) * compare the definition of R1 * * abstract *	1-10	
Y	----- US 4 563 449 A (TERAJI TSUTOMU [JP] ET AL) 7 January 1986 (1986-01-07) * compare the definition of R1 and R3, see claims * * the whole document *	1-10	
T	----- ISHIKAWA T ET AL: "STUDIES ON ANTI-MRSA PARENTERAL CEPHALOSPORINS IV. A NOVEL WATER-SOLUBLE N-PHOSPHONO TYPE PRODRUG FOR PARENTERAL ADMINISTRATION" JOURNAL OF ANTIBIOTICS, JAPAN ANTIBIOTICS RESEARCH ASSOCIATION, TOKYO, JP, vol. 54, no. 4, 1 April 2001 (2001-04-01), pages 364-374, XP001022055 ISSN: 0021-8820 * see p.364, abstract, "N-modified prodrug strategy"; par. bridging p.364/365, * * the whole document *	1-10	
			TECHNICAL FIELDS SEARCHED (IPC)
The present search report has been drawn up for all claims			
Place of search Munich		Date of completion of the search 4 June 2009	Examiner Stellmach, Joachim
<p>CATEGORY OF CITED DOCUMENTS</p> <p>X : particularly relevant if taken alone Y : particularly relevant if combined with another document of the same category A : technological background O : non-written disclosure P : intermediate document</p> <p>T : theory or principle underlying the invention E : earlier patent document, but published on, or after the filing date D : document cited in the application L : document cited for other reasons & : member of the same patent family, corresponding document</p>			

3
EPO FORM 1503 (03.02) (P4/C01)

ANNEX TO THE EUROPEAN SEARCH REPORT
ON EUROPEAN PATENT APPLICATION NO.

EP 09 15 8866

This annex lists the patent family members relating to the patent documents cited in the above-mentioned European search report.
The members are as contained in the European Patent Office EDP file on
The European Patent Office is in no way liable for these particulars which are merely given for the purpose of information.

04-06-2009

Patent document cited in search report		Publication date	Patent family member(s)	Publication date
JP 10265488	A	06-10-1998	NONE	
JP 09100283	A	15-04-1997	JP 3927262 B2	06-06-2007
EP 0099553	A	01-02-1984	DE 3380627 D1	02-11-1989
			DE 3382621 D1	15-10-1992
			DE 3382621 T2	18-02-1993
			EP 0300121 A2	25-01-1989
			JP 2029283 C	19-03-1996
			JP 3007296 A	14-01-1991
			JP 7051591 B	05-06-1995
			JP 1755386 C	23-04-1993
			JP 3007292 A	14-01-1991
			JP 4048796 B	07-08-1992
			US 4563449 A	07-01-1986
			US 4654422 A	31-03-1987
			US 4772682 A	20-09-1988
EP 0007470	A	06-02-1980	AR 226539 A1	30-07-1982
			AU 533708 B2	08-12-1983
			AU 4869579 A	07-02-1980
			DE 2966293 D1	17-11-1983
			DK 289079 A	11-01-1980
			EP 0036673 A1	30-09-1981
			ES 482323 A1	16-08-1980
			ES 8103102 A1	16-05-1981
			ES 8103072 A1	16-05-1981
			HU 183010 B	28-04-1984
			JP 1700082 C	14-10-1992
			JP 3068028 B	25-10-1991
			JP 63264471 A	01-11-1988
			US 4268509 A	19-05-1981
			US 4447429 A	08-05-1984
			US 4585872 A	29-04-1986
JP 62238291	A	19-10-1987	NONE	
US 4563449	A	07-01-1986	DE 3380627 D1	02-11-1989
			DE 3382621 D1	15-10-1992
			DE 3382621 T2	18-02-1993
			EP 0099553 A2	01-02-1984
			EP 0300121 A2	25-01-1989
			JP 2029283 C	19-03-1996
			JP 3007296 A	14-01-1991
			JP 7051591 B	05-06-1995
			JP 1755386 C	23-04-1993

EPO FORM P 0489

For more details about this annex : see Official Journal of the European Patent Office, No. 12/82

**ANNEX TO THE EUROPEAN SEARCH REPORT
ON EUROPEAN PATENT APPLICATION NO.**

EP 09 15 8866

This annex lists the patent family members relating to the patent documents cited in the above-mentioned European search report. The members are as contained in the European Patent Office EDP file on
The European Patent Office is in no way liable for these particulars which are merely given for the purpose of information.

04-06-2009

Patent document cited in search report	Publication date	Patent family member(s)	Publication date
US 4563449 A		JP 3007292 A	14-01-1991
		JP 4048796 B	07-08-1992
		US 4654422 A	31-03-1987
		US 4772682 A	20-09-1988

EPO FORM P0469

For more details about this annex : see Official Journal of the European Patent Office, No. 12/82

REFERENCES CITED IN THE DESCRIPTION

This list of references cited by the applicant is for the reader's convenience only. It does not form part of the European patent document. Even though great care has been taken in compiling the references, errors or omissions cannot be excluded and the EPO disclaims all liability in this regard.

Patent documents cited in the description

- JP H91997100283 A [0002]
- JP S59198431791 A [0003]
- JP S601985231684 A [0047]
- JP S621987149682 A [0047]
- EP 0590681 A [0047]

Non-patent literature cited in the description

- *The Journal of The American Chemical Society*, 1962, vol. 84, 3400 [0007]
- The Pharmacopoeia of Japan [0086]

HKP1020054

发明名称:

磷酰化头孢衍生物、其制备和应用

摘要:

本发明提供 7β -[2(Z)-乙氧基亚氨基-2-(5-磷酰氨基-1,2,4-噻二唑-3-基)乙酰胺基]-3-[4-(1-甲基-4-吡啶基)-2-噻唑基硫基]-3-头孢-4-甲酸, 其酯或其盐, 其具有较强抗菌活性、稳定性、可吸收性等。本发明还提供含有上述化合物的药物组合物。